Indonesia vs Nauru: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Indonesia
69.0%
in 2025
Nauru
66.0%
in 2025
Indonesia rank
133rd
Nauru rank
136th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Indonesia
- Nauru
How they compare
Indonesia currently reports 69.0% against 66.0% in Nauru, a difference of 3.0%.
The two have swapped places 3 times across 18 shared years of data; in 2008 it was Nauru ahead.
Indonesia ranks 133rd and Nauru ranks 136th of 192 countries.
Across the 3 decades both report, Indonesia averaged higher in 1 and Nauru in 1.
Head to head by decade
| Decade | Indonesia | Nauru | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | β |
| 2010s | 0.3% | 0.0% | 0.3% | Indonesia |
| 2020s | 30.2% | 62.7% | 32.5% | Nauru |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Indonesia or Nauru?
- Indonesia, at 69.0% against 66.0% in Nauru as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Indonesia and Nauru?
- 3.0%, with Indonesia ahead.
- How many years of comparable data are there for Indonesia and Nauru?
- 18 years are reported by both, from 2008 to 2025.
- How do Indonesia and Nauru rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Indonesia ranks 133rd and Nauru ranks 136th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.